We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Peptide Biomarker Predicts Risk of Dying in Patients with Stable Heart Failure

By LabMedica International staff writers
Posted on 13 Jan 2020
Cardiovascular disease researchers have identified a biomarker that predicts when a patient with chronic stable heart failure (CHF) is likely to die.

Individuals with stable CHF have suffered damage to their heart muscles but do not usually require hospitalization. While these individuals are at increased risk of dying within five years from the time of injury, some experience rapid disease progression while others remain in a stable condition.

Image: NMR solution structure of neuropeptide Y (Photo courtesy of Wikimedia Commons)
Image: NMR solution structure of neuropeptide Y (Photo courtesy of Wikimedia Commons)

Investigators at the University of California, Los Angeles (USA) searched for biomarkers that could distinguish between these two classes of CHF patients. To this end, they analyzed blood samples from 105 patients with stable heart failure, searching for a distinct biomarker in the blood that could predict how likely a person would be to die within a few years. The investigators examined coronary sinus (CS) blood in a prospective cohort of patients with stable CHF at the time of elective cardiac resynchronization therapy (CRT) device implantation, during which the CS was readily accessible. Coronary sinus blood was chosen for sampling over peripheral venous blood to avoid the potential contaminating effect of other tissues such as the gastrointestinal tract. The mean age of the patients was 68 years and 82 (78%) were men.

Results revealed that neuropeptide Y levels were the clearest and most significant predictor of which patients were most likely to die within one to three years. Neuropeptide Y (NPY) is a 36 amino-acid neuropeptide that is involved in various physiological and homeostatic processes in both the central and peripheral nervous systems. NPY has been identified as the most abundant peptide present in the mammalian central nervous system, which consists of the brain and spinal cord. It is secreted alongside other neurotransmitters such as GABA and glutamate.

Overall, findings obtained during this study indicated that patients with higher levels of neuropeptide Y were nearly 10 times more likely to die within one to three years than those with lower levels of NPY. Thus, determination of NPY level could serve as a tool to distinguish very-high-risk patients with stable heart failure from lower risk patients with the same condition. This information would identify those patients requiring more aggressive and targeted therapies.

The study was published in the December 26, 2019, online edition of the journal JAMA Cardiology.

Related Links:
University of California, Los Angeles


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
New
Automated Nucleic Acid Extractor
eLab

Latest Molecular Diagnostics News

Smarter Blood Tests Deliver Faster Diagnoses and Improved Outcomes

Single Metagenomic Next-Generation Sequencing Test Can Detect All Infectious Pathogens

Cutting-Edge Diagnostic Tool Rapidly Identifies Emerging SARS-CoV-2 Variants